OR WAIT null SECS
© 2021 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Complex biotherapeutics present unique analytical challenges for developers.
EMA starts review of Sanofi vaccine; Regeneron's EUA expanded
Public-private consortium is tasked with advancing domestic pharmaceutical production.
New biotherapeutics both drive and benefit from innovative development technologies.
August 05, 2021
BMG Pharma's clinical trial has demonstrated positive results in the efficacy of BMG0705 Nasal Spray and BMG0703A Mouth Rinse as treatments for asymptomatic COVID-19 patients.
Evonik has acquired the German biotech company JeNaCell, expanding its biomaterials portfolio.
Nanoform and Boehringer Ingelheim have executed a master services agreement in relation to pre-clinical development projects.
A research collaboration will combine Imugene’s oncolytic virus technology with Celularity’s allogeneic CAR T-cell therapy.
EC has confirmed that the entry into application of the Clinical Trials Regulation and, as such, the go-live date for the Clinical Trials Information System (CTIS) will be Jan. 31, 2022.
WuXi STA has finalized its acquisition of Bristol Myers Squibb’s drug product manufacturing facility based in Couvet, Switzerland.
August 04, 2021
Bristol Myers Squibb has been granted approval by the European Commission for Opdivo (nivolumab) as an adjuvant treatment
EMA’s CHMP has approved the increased manufacturing capacity and supply of Moderna’s COVID-19 vaccine active substance in its US manufacturing site.
Bioiberica has received certification of its CSR management system as aligned with the United Nations Sustainable Development Goals.
The University of Sheffield has launched an innovative gene therapy program that could pave the way for novel treatments for neurodegenerative diseases.